Idarucizumab
Sign in to saveAlso known as Praxbind
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Key facts
- Drug.pregnancy_AU
- B2
- Drug.type
- mab
- Drug.mab_type
- Fab
- Drug.source
- zu/o
- Drug.target
- Dabigatran
- Drug.tradename
- Praxbind
- Drug.DailyMedID
- Idarucizumab
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- V03
- Drug.ATC_suffix
- AB37
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 1362509-93-0
- Drug.IUPHAR_ligand
- 8298
- Drug.DrugBank
- DB09264
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 4 more facts
- World Health Organisation international non-proprietary name
- idarucizumab
- stylized name
- idaruCIZUmab
- has characteristic
- biopharmaceutical
- subject has role
- monoclonal antibody
via Wikidata · CC0
~2 min read
Encyclopedic overview
7 sectionsContents
- Mechanism of action
- Medical uses
- Adverse effects
- Pregnancy
- Society and culture
- Names
- References
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.
Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.
Excerpted from Wikipedia’s “Idarucizumab” article, available under the CC BY-SA 4.0 licence.